Furthermore, PAH patients with SOX17 mutations demonstrate high rates of dilated and tortuous pulmonary vessels, hemoptysis and atrial and ventricular septal defects (Figure 6). This evidence concerns the gene SOX17 and pulmonary arterial hypertension.